Literature DB >> 29122934

Genotyping Natural Killer Immune Checkpoints to Discover Biomarkers of Response.

Nai-Kong Cheung1, Katharine C Hsu2.   

Abstract

Immune checkpoints have been a focus of immunotherapy in the recent decade. Killer cell immunoglobulin-like receptors (KIR) and their cognate human leukocyte antigen (HLA) class I ligands have evolved as checkpoints to ensure self-tolerance of natural killer cells. Both KIR and HLA genetic profiles are potential biomarkers of immunotherapy outcome. Clin Cancer Res; 24(1); 3-5. ©2017 AACRSee related article by Erbe et al., p. 189. ©2017 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29122934      PMCID： PMC5754255          DOI： 10.1158/1078-0432.CCR-17-2884

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Authors:  Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert Seeger; C Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan L Cohn; John M Maris; Paul M Sondel
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

Review 2.  NK cells and cancer: you can teach innate cells new tricks.

Authors:  Maelig G Morvan; Lewis L Lanier
Journal:  Nat Rev Cancer       Date:  2016-01       Impact factor: 60.716

3.  Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

Authors:  David C Delgado; Jacquelyn A Hank; Jill Kolesar; David Lorentzen; Jacek Gan; Songwon Seo; Kyungmann Kim; Suzanne Shusterman; Stephen D Gillies; Ralph A Reisfeld; Richard Yang; Brian Gadbaw; Kenneth B DeSantes; Wendy B London; Robert C Seeger; John M Maris; Paul M Sondel
Journal:  Cancer Res       Date:  2010-10-08       Impact factor: 12.701

4.  Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications.

Authors:  Lizzia Raffaghello; Ignazia Prigione; Paola Bocca; Fabio Morandi; Marta Camoriano; Claudio Gambini; Xinhui Wang; Soldano Ferrone; Vito Pistoia
Journal:  Oncogene       Date:  2005-07-07       Impact factor: 9.867

5.  NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.

Authors:  Zane C Neal; Michael Imboden; Alexander L Rakhmilevich; Kyung-Mann Kim; Jacquelyn A Hank; Jean Surfus; John R Dixon; Holger N Lode; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2003-09-18       Impact factor: 6.968

Review 6.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Authors:  Nai-Kong V Cheung; Michael A Dyer
Journal:  Nat Rev Cancer       Date:  2013-06       Impact factor: 60.716

7.  KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.

Authors:  Christopher J Forlenza; Jeanette E Boudreau; Junting Zheng; Jean-Benoît Le Luduec; Elizabeth Chamberlain; Glenn Heller; Nai-Kong V Cheung; Katharine C Hsu
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

8.  Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.

Authors:  Nai-Kong V Cheung; Irene Y Cheung; Brian H Kushner; Irina Ostrovnaya; Elizabeth Chamberlain; Kim Kramer; Shakeel Modak
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

9.  Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

Authors:  Amy K Erbe; Wei Wang; Lakeesha Carmichael; KyungMann Kim; Eneida A Mendonça; Yiqiang Song; Dustin Hess; Patrick K Reville; Wendy B London; Arlene Naranjo; Jacquelyn A Hank; Mitchell B Diccianni; Ralph A Reisfeld; Stephen D Gillies; Katherine K Matthay; Susan L Cohn; Michael D Hogarty; John M Maris; Julie R Park; M Fevzi Ozkaynak; Andrew L Gilman; Alice L Yu; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2017-10-02       Impact factor: 12.531

10.  Differentiation induced by physiological and pharmacological stimuli leads to increased antigenicity of human neuroblastoma cells.

Authors:  Lena-Maria Carlson; Sven Påhlman; Anna De Geer; Per Kogner; Jelena Levitskaya
Journal:  Cell Res       Date:  2008-03       Impact factor: 25.617
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.